In an effort to encourage more blood donations, the Food and Drug Administration today said it is revisiting and updating several existing policies to help ensure an adequate-but-safe national blood supply.

To account for COVID-19, the agency is providing notice of alternatives to certain blood donor eligibility requirements for the duration of the pandemic. Among other changes, the guidance allows blood centers to reduce donation deferral periods for certain categories of blood donors from 12 months to three. FDA said it will provide notification when the alternative procedures are no longer in effect.

FDA also issued the following:

According to the agency, these recommendations are expected to remain in place after the COVID-19 pandemic ends, with any appropriate changes based on comments FDA receives.

Related News Articles

Headline
Proactive COVID-19 testing of all long-term care staff and residents, who are usually at higher risk of contracting the virus, may help prevent potential…
Headline
The Food and Drug Administration yesterday approved a new drug application for propofol injectable emulsion, an intravenous general anesthetic and sedation…
Headline
In a sample of 598 hospitalized pregnant women with COVID-19, 55% had no symptoms on admission, according to a report released this week by the Centers for…
Headline
The Centers for Disease Control and Prevention today updated its testing guidance for SARS-CoV-2, the virus that causes COVID-19. “Due to the significance of…
Headline
The Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response recently posted new and updated COVID-19 resources…
Headline
The Food and Drug Administration this week approved dexmedetomidine hydrochloride in 0.9% sodium chloride injection for the sedation of initially intubated and…